Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited)

v3.21.2
Condensed Consolidated Interim Statements of Loss and Comprehensive Loss (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Revenue $ 0 $ 0 $ 0 $ 0
Expenses:        
Research and development 7,718 7,519 25,777 20,319
General and administrative 3,641 5,775 15,322 20,690
Operating expenses 11,359 13,294 41,099 41,009
Other income (expense):        
Interest income 22 46 72 485
Foreign exchange gains/(losses) 4 (1) (3) (1)
Total other income 26 45 69 484
Net loss (11,333) (13,249) (41,030) (40,525)
Other comprehensive gain/(loss):        
Unrealized loss on securities available-for-sale 0 (2) 0 (17)
Total comprehensive loss $ (11,333) $ (13,251) $ (41,030) $ (40,542)
Basic and diluted loss per common share (in dollars per share) $ (0.13) $ (0.15) $ (0.46) $ (0.51)
Weighted average number of common shares outstanding used in the calculation of (in thousands)        
Basic and diluted loss per common share (in shares) 88,949 85,860 88,927 79,477